Reults from a new study investigating the benefits of Sativex in neuropathic pain in people with Multiple Sclerosis (MS) have shown it gave long term relief. The study followed 42 people with MS who used Sativex. This randomized withdrawl study evaluated the participants who had previously been in a Sativex MS neuropathic pain study and who continued to use Sativex for 12 weeks. They were then randomized to Sativex or placebo for a further 4 weeks in a double-blinded manner. The study found that people using the Sativex maintained or improved their response whereas the symptoms of those using the placebo worsened. The placebo grooup reported significantly higher levels of pain. This trial is important as it further reinforces early clinical evidence that suggests Sativex may be effective for pain in MS.